5-Hydroxy-1-methylhydantoin

TargetMol
Product Code: TAR-T28222
Supplier: TargetMol
CodeSizePrice
TAR-T28222-1mg1mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28222-1mL1 mL * 10 mM (in DMSO)£258.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28222-5mg5mg£340.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28222-10mg10mg£466.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28222-25mg25mg£705.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28222-50mg50mg£970.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28222-100mg100mg£1,267.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28222-500mg500mg£2,456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
NZ-419 is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, NZ-419, a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. NZ-419 a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. NZ-419 inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that NZ-419 may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.
CAS:
84210-26-4
Formula:
C4H6N2O2
Molecular Weight:
114.1
Pathway:
GPCR/G Protein
Purity:
0.995
SMILES:
O=C1NC(CN1C)=O
Target:
Bradykinin Receptor

References

1. Ienaga K, Sohn M, Naiki M, Jaffa AA. Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells. J Recept Signal Transduct Res. 2014 Jun;34(3):195-200. 2. Ienaga K, Park CH, Yokozawa T. Protective effect of an intrinsic antioxidant, HMH (5-hydroxy-1-methylhydantoin; NZ-419), against cellular damage of kidney tubules. Exp Toxicol Pathol. 2013 Jul;65(5):559-66. doi: 10.1016/j.etp.2012.05.001. PubMed PMID: 22749566. 3. Ienaga K, Yokozawa T. Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75. PubMed PMID: 22466296. 4. Hasegawa G, Nakano K, Ienaga K. Serum accumulation of a creatinine oxidative metabolite (NZ-419: 5-hydroxy-1- methylhydatoin) as an intrinsic antioxidant in diabetic patients with or without chronic kidney disease. Clin Nephrol. 2011 Oct;76(4):284-9. PubMed PMID: 21955863.